Skip to main content
. 2016 Jun 21;17:293. doi: 10.1186/s13063-016-1423-0

Fig. 1.

Fig. 1

Schematic representation of the study. In Part 1 patients with advanced disease will be enrolled to be administered carboplatin and olaparib in two 3-weekly cycles followed by olaparib monotherapy until dose limiting toxicity or progressive disease. The maximum tolerable dose will be determined